John A Bonino1, Prateek Sharma. 1. Division of Gastroenterology and Hepatology, University of Kansas School of Medicine and Veterans Affairs Medical Center, Kansas City, Missouri, USA.
Abstract
PURPOSE OF REVIEW: Barrett's esophagus continues to be a popular topic among clinicians and researchers alike. Population based studies have finally been undertaken to better identify subset populations at high risk of developing Barrett's esophagus, and possible better tolerated alternatives to standard endoscopy for cost-effective screening. In addition, several studies over the past year have marked a transition from identifying those with Barrett's esophagus and in need of intensive surveillance, to an increasing number of novel treatment therapies that are now primed to move from experimental protocols to clinical practice. RECENT FINDINGS: Obesity's role as a risk factor for the development of Barrett's esophagus continues to be better defined. Various disorders affecting the motility of the gastrointestinal tract, such as celiac sprue and scleroderma, and their relationship with Barrett's esophagus development are becoming more widely recognized. The use of endoscopic mucosal resection and photodynamic therapy for treatment of dysplastic Barrett's esophagus continues to gain increased acceptance, with an additional wealth of supportive data for its effectiveness becoming available. SUMMARY: The past year has brought many advances in the epidemiology and endoscopic treatment of those with Barrett's esophagus. Clinicians will benefit from this review of these advances to ensure better patient outcomes.
PURPOSE OF REVIEW: Barrett's esophagus continues to be a popular topic among clinicians and researchers alike. Population based studies have finally been undertaken to better identify subset populations at high risk of developing Barrett's esophagus, and possible better tolerated alternatives to standard endoscopy for cost-effective screening. In addition, several studies over the past year have marked a transition from identifying those with Barrett's esophagus and in need of intensive surveillance, to an increasing number of novel treatment therapies that are now primed to move from experimental protocols to clinical practice. RECENT FINDINGS: Obesity's role as a risk factor for the development of Barrett's esophagus continues to be better defined. Various disorders affecting the motility of the gastrointestinal tract, such as celiac sprue and scleroderma, and their relationship with Barrett's esophagus development are becoming more widely recognized. The use of endoscopic mucosal resection and photodynamic therapy for treatment of dysplastic Barrett's esophagus continues to gain increased acceptance, with an additional wealth of supportive data for its effectiveness becoming available. SUMMARY: The past year has brought many advances in the epidemiology and endoscopic treatment of those with Barrett's esophagus. Clinicians will benefit from this review of these advances to ensure better patient outcomes.
Authors: Antonie D Kline; Marco Grados; Paul Sponseller; Howard P Levy; Natalie Blagowidow; Christianne Schoedel; Joni Rampolla; Douglas K Clemens; Ian Krantz; Amy Kimball; Carmen Pichard; David Tuchman Journal: Am J Med Genet C Semin Med Genet Date: 2007-08-15 Impact factor: 3.908